stockportfolio.pro
Stocks / DVA vs GMAB
DVA vs GMAB
DaVita Inc. and Genmab A/S side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| DaVita Inc. (DVA) | Genmab A/S (GMAB) | |
|---|---|---|
| Market cap | $13.5B | $15.3B |
| Revenue (latest FY) | $13.64B | $3.72B |
| Net income (latest FY) | $746.80M | $963.00M |
| Revenue growth (5y CAGR) | 3.4% | 21.2% |
| Net margin | 5.5% | 25.9% |
| Return on equity | -114.7% | 16.5% |
| P/E ratio | 20.2 | 19.1 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 10 | 4 |
| Positive free cash flow | Yes | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open DVA — free Open GMAB — freeFrequently asked questions
Which is bigger, DVA or GMAB?
Genmab A/S is larger by market capitalization — $15.3B versus $13.5B.
Which grows faster, DVA or GMAB?
Over the last five fiscal years, Genmab A/S grew revenue faster — 21.2%/yr versus 3.4%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.